instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
What is the median PFS rate in patients who have undergone Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). | ### Instruction: What is the median PFS rate in patients who have undergone Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). |
What’s the median PFS rate for patients receiving Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). | ### Instruction: What’s the median PFS rate for patients receiving Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). |
Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). |
What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). |
Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). |
What is the median PFS rate for patients that have undergone Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). | ### Instruction: What is the median PFS rate for patients that have undergone Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). |
Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). |
What’s the median rate of PFS in patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). | ### Instruction: What’s the median rate of PFS in patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). |
Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4). |
Can you tell me the median PFS for High-Dose Melphalan? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for High-Dose Melphalan?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What’s the median PFS associated with High-Dose Melphalan? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with High-Dose Melphalan?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Could you provide the median PFS of High-Dose Melphalan? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of High-Dose Melphalan?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
I’d like to know the median PFS of High-Dose Melphalan. | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of High-Dose Melphalan.
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Do you have information on the median PFS of High-Dose Melphalan? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of High-Dose Melphalan?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for High-Dose Melphalan? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for High-Dose Melphalan?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Can you inform me about the median PFS for High-Dose Melphalan? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for High-Dose Melphalan?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
I’m interested in the median PFS of High-Dose Melphalan. | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of High-Dose Melphalan.
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Could you tell me the median PFS for High-Dose Melphalan? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for High-Dose Melphalan?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median PFS rate for High-Dose Melphalan? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for High-Dose Melphalan?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What’s the median PFS rate for patients receiving High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What’s the median PFS rate for patients receiving High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Could you provide the median Progression-Free Survival rate for patients treated with High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median rate of Progression-Free Survival in patients who have been treated with High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Can you inform me about the median PFS rate in patients that were treated with High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What is the median PFS rate for patients that have undergone High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for patients that have undergone High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Could you tell me the median Progression-Free Survival rate for patients who received High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
What’s the median rate of PFS in patients treated with High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: What’s the median rate of PFS in patients treated with High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Can you share the median Progression-Free Survival rate in patients who have received High-Dose Melphalan regimen? | Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received High-Dose Melphalan regimen?
### Response: Patients treated with the High-Dose Melphalan have a median Progression-Free Survival (PFS) rate of None months, with a 95% CI of None. |
Can you tell me the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: Can you tell me the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
What’s the median PFS associated with Pomalidomide+Bortezomib+Dexamethasone (PVd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: What’s the median PFS associated with Pomalidomide+Bortezomib+Dexamethasone (PVd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
Could you provide the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: Could you provide the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
I’d like to know the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd). | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: I’d like to know the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd).
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
Do you have information on the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: Do you have information on the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
What is the median progression-free survival (PFS) for Pomalidomide+Bortezomib+Dexamethasone (PVd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: What is the median progression-free survival (PFS) for Pomalidomide+Bortezomib+Dexamethasone (PVd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
Can you inform me about the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: Can you inform me about the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
I’m interested in the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd). | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: I’m interested in the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd).
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
Could you tell me the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: Could you tell me the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
What is the median PFS rate for Pomalidomide+Bortezomib+Dexamethasone (PVd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: What is the median PFS rate for Pomalidomide+Bortezomib+Dexamethasone (PVd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
What is the median PFS rate in patients who have undergone Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: What is the median PFS rate in patients who have undergone Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
What’s the median PFS rate for patients receiving Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: What’s the median PFS rate for patients receiving Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
What is the median PFS rate for patients that have undergone Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: What is the median PFS rate for patients that have undergone Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
What’s the median rate of PFS in patients treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: What’s the median rate of PFS in patients treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
Can you share the median Progression-Free Survival rate in patients who have received Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Pomalidomide+Bortezomib+Dexamethasone (PVd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (9.66, 13.73). |
Can you tell me the median PFS for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: Can you tell me the median PFS for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
What’s the median PFS associated with Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: What’s the median PFS associated with Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
Could you provide the median PFS of Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: Could you provide the median PFS of Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
I’d like to know the median PFS of Bortezomib+Dexamethasone (Vd). | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: I’d like to know the median PFS of Bortezomib+Dexamethasone (Vd).
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
Do you have information on the median PFS of Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: Do you have information on the median PFS of Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
What is the median progression-free survival (PFS) for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: What is the median progression-free survival (PFS) for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
Can you inform me about the median PFS for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: Can you inform me about the median PFS for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
I’m interested in the median PFS of Bortezomib+Dexamethasone (Vd). | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: I’m interested in the median PFS of Bortezomib+Dexamethasone (Vd).
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
Could you tell me the median PFS for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: Could you tell me the median PFS for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
What is the median PFS rate for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: What is the median PFS rate for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
What is the median PFS rate in patients who have undergone Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: What is the median PFS rate in patients who have undergone Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
What’s the median PFS rate for patients receiving Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: What’s the median PFS rate for patients receiving Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
What is the median PFS rate for patients that have undergone Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: What is the median PFS rate for patients that have undergone Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
What’s the median rate of PFS in patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: What’s the median rate of PFS in patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (5.88, 8.48). |
Can you tell me the median PFS for Daratumumab 16 Mg/Kg? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: Can you tell me the median PFS for Daratumumab 16 Mg/Kg?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
What’s the median PFS associated with Daratumumab 16 Mg/Kg? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: What’s the median PFS associated with Daratumumab 16 Mg/Kg?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
Could you provide the median PFS of Daratumumab 16 Mg/Kg? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: Could you provide the median PFS of Daratumumab 16 Mg/Kg?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
I’d like to know the median PFS of Daratumumab 16 Mg/Kg. | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: I’d like to know the median PFS of Daratumumab 16 Mg/Kg.
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
Do you have information on the median PFS of Daratumumab 16 Mg/Kg? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: Do you have information on the median PFS of Daratumumab 16 Mg/Kg?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
What is the median progression-free survival (PFS) for Daratumumab 16 Mg/Kg? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: What is the median progression-free survival (PFS) for Daratumumab 16 Mg/Kg?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
Can you inform me about the median PFS for Daratumumab 16 Mg/Kg? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: Can you inform me about the median PFS for Daratumumab 16 Mg/Kg?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
I’m interested in the median PFS of Daratumumab 16 Mg/Kg. | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: I’m interested in the median PFS of Daratumumab 16 Mg/Kg.
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
Could you tell me the median PFS for Daratumumab 16 Mg/Kg? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: Could you tell me the median PFS for Daratumumab 16 Mg/Kg?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
What is the median PFS rate for Daratumumab 16 Mg/Kg? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: What is the median PFS rate for Daratumumab 16 Mg/Kg?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
What is the median PFS rate in patients who have undergone Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: What is the median PFS rate in patients who have undergone Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
What’s the median PFS rate for patients receiving Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: What’s the median PFS rate for patients receiving Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
Can you inform me about the median PFS rate in patients that were treated with Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
What is the median PFS rate for patients that have undergone Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: What is the median PFS rate for patients that have undergone Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
What’s the median rate of PFS in patients treated with Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: What’s the median rate of PFS in patients treated with Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
Can you share the median Progression-Free Survival rate in patients who have received Daratumumab 16 Mg/Kg regimen? | Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Daratumumab 16 Mg/Kg regimen?
### Response: Patients treated with the Daratumumab 16 Mg/Kg have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (2.8, 4.6). |
Can you tell me the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: Can you tell me the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
What’s the median PFS associated with Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: What’s the median PFS associated with Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
Could you provide the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: Could you provide the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
I’d like to know the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd). | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: I’d like to know the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd).
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
Do you have information on the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: Do you have information on the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
What is the median progression-free survival (PFS) for Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: What is the median progression-free survival (PFS) for Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
Subsets and Splits